Fluoroquinolone-resistant and extended-spectrum β-lactamase- producing escherichia coli infections in patients with pyelonephritis, United States

Emerging Infectious Diseases

Volumn 22, Issue 9, 2016, Pages 1594-1603

  Talan, David A ^a,b   Takhar, Sukhjit S ^c,d   Krishnadasan, Anusha ^a,b   Abrahamian, Fredrick M ^a,b   Mower, William R ^a,e   Moran, Gregory J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFAZOLIN; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; QUINOLONE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; COMMUNITY ACQUIRED INFECTION; CROSS-SECTIONAL STUDY; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; FLANK PAIN; FLUOROQUINOLONE RESISTANCE; HEALTHCARE ASSOCIATED INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREVALENCE; PROSPECTIVE STUDY; PYELONEPHRITIS; UNITED STATES; URINARY TRACT INFECTION; URINE CULTURE; ADOLESCENT; BIOSYNTHESIS; DRUG EFFECTS; ESCHERICHIA COLI; GENETICS; HEALTH SURVEY; HOSPITAL EMERGENCY SERVICE; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EMERGENCY SERVICE, HOSPITAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREVALENCE; PYELONEPHRITIS; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84988344385     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2209.160148     Document Type: Article

References (24)

1. Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA. 2000;283:1583-90. http://dx.doi.org/10.1001/jama.283.12.1583
2. Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Weshnoweski B, et al.; NAUTICA Group. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents. 2006;27:468-75. http://dx.doi.org/10.1016/j.ijantimicag.2006.02.009
3. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother. 2012;56:2181-3. http://dx.doi.org/10.1128/AAC.06060-11
4. Dalhoff A. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip Perspect Infect Dis. 2012;2012:976273.
5. Johnson SW, Anderson DJ, May DB, Drew RH. Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum β-lactamase-producing enterobacteriaceae on hospital admission. Infect Control Hosp Epidemiol. 2013;34:385-92. http://dx.doi.org/10.1086/669858
6. Hayakawa K, Gattu S, Marchaim D, Bhargava A, Palla M, Alshabani K, et al. Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large U.S. Medical Center. Antimicrob Agents Chemother. 2013;57:4010-8. http://dx.doi.org/10.1128/AAC.02516-12
7. Doi Y, Park YS, Rivera JI, Adams-Haduch JM, Hingwe A, Sordillo EM, et al. Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis. 2013;56:641-8. http://dx.doi.org/10.1093/cid/cis942
8. Peirano G, van der Bij AK, Gregson DB, Pitout JD. Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum β-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol. 2012;50:294-9. http://dx.doi.org/10.1128/JCM.06025-11
9. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al.; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103-20. http://dx.doi.org/10.1093/cid/ciq257
10. Shin J, Kim J, Wie SH, Cho YK, Lim SK, Shin SY, et al. Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact. Microb Drug Resist. 2012;18:169-75. http://dx.doi.org/10.1089/mdr.2011.0139
11. Lee S, Song Y, Cho SH, Kwon KT. Impact of extended-spectrum beta-lactamase on acute pyelonephritis treated with empirical ceftriaxone. Microb Drug Resist. 2014;20:39-44. http://dx.doi.org/10.1089/mdr.2013.0075
12. Talan DA, Moran GJ, Mower W, Newdow M, Ong S, Slutsker L, et al.; The EMERGEncy ID NET Study Group. EMERGEncy ID NET: an emergency department-based emerging infections sentinel network. Ann Emerg Med. 1998;32:703-11. http://dx.doi.org/10.1016/S0196-0644(98)70071-X
13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. CLSI document M100-S22. Wayne (PA): The Institute; 2012.
14. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-81. http://dx.doi.org/10.1016/j.jbi.2008.08.010
15. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ; EMERGEncy ID NET Study Group. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis. 2008;47:1150-8. http://dx.doi.org/10.1086/592250
16. Bedoin M, Cazorla C, Lucht F, Berthelot P, Boyer M, Carricajo A, et al. Risk factors for quinolone-resistance in women presenting with Escherichia coli acute pyelonephritis. Med Mal Infect. 2014;44:206-16. http://dx.doi.org/10.1016/j.medmal.2014.02.003
17. van der Starre WE, van Nieuwkoop C, Paltansing S, van’t Wout JW, Groeneveld GH, Becker MJ, et al. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother. 2011;66:650-6. http://dx.doi.org/10.1093/jac/dkq465
18. Johnson JR, Urban C, Weissman SJ, Jorgensen JH, Lewis JS II, Hansen G, et al.; AMERECUS Investigators. Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob Agents Chemother. 2012;56:2364-70. http://dx.doi.org/10.1128/AAC.05824-11
19. Peirano G, Costello M, Pitout JD. Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals. Int J Antimicrob Agents. 2010;36:19-23. http://dx.doi.org/10.1016/j.ijantimicag.2010.02.016
20. Khawcharoenporn T, Vasoo S, Singh K. Urinary tract infections due to multidrug-resistant Enterobacteriaceae: prevalence and risk factors in a Chicago emergency department. Emerg Med Int. 2013;2013:258517.
21. Søraas A, Sundsfjord A, Sandven I, Brunborg C, Jenum PA. Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae—a case-control study in a low prevalence country. PLoS One. 2013;8:e69581. http://dx.doi.org/10.1371/journal.pone.0069581
22. Azap OK, Arslan H, Serefhanoğlu K, Colakoğlu S, Erdoğan H, Timurkaynak F, et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect. 2010;16:147-51. http://dx.doi.org/10.1111/j.1469-0691.2009.02941.x
23. Banerjee R, Strahilevitz J, Johnson JR, Nagwekar PP, Schora DM, Shevrin I, et al. Predictors and molecular epidemiology of community-onset extended-spectrum β-lactamase- producing Escherichia coli infection in a Midwestern community. Infect Control Hosp Epidemiol. 2013;34:947-53. http://dx.doi.org/10.1086/671725
24. Huang Y, Carroll KC, Cosgrove SE, Tamma PD. Determining the optimal ceftriaxone MIC for triggering extended-spectrum β-lactamase confirmatory testing. J Clin Microbiol. 2014;52:2228-30. http://dx.doi.org/10.1128/JCM.00716-14